Laureate Institute for Brain Research
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Laureate Institute for Brain Research sits in the top decile of US sponsors by registered trial count (#397 of 15,742 sponsors by registered trial count).
Laureate Institute for Brain Research: 45 sponsored US clinical trials, 14 recruiting.
Laureate Institute for Brain Research sponsors 45 registered US clinical trials on ClinicalTrials.gov, 14 of them currently recruiting, and 27 completed. 2 of these trials are in Phase 3-4 (later-stage) and 8 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Depression, with 5 trials.
Top-decile sponsor footprint
Laureate Institute for Brain Research ranks in the top decile of sponsors by registered trial count (#397 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
27 of 31 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (87.1%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
45 total, page 1 of 1
LIFU Mechanisms for PTSD in Healthcare Workers
NCT07164105
Decoding Emotional Dynamics in Bipolar Disorder
NCT07221864
Ultrasound Neuromodulation of Circuits and Negative Valence Systems in Treatment-Resistant Depression
NCT07166289
Dose-Dependent Effects of Low-Intensity Focused Ultrasound
NCT07099950
Mood and Decision-making in Methamphetamine Use Disorder
NCT06410196
Interoceptive Mechanisms of Body Image Disturbance in Anorexia Nervosa
NCT06332963
Effects of Acute Exercise and Ibuprofen on Symptoms, Immunity, and Neural Circuits in Bipolar Depression
NCT06088732
Evaluation of a Keto-Like Supplement on Brain Responses to Emotional Stimuli in Depression
NCT06263660
Processes and Circuitry Underlying Threat Sensitivity as a Treatment Target for Co-morbid Anxiety and Depression
NCT06004115
Amplification of Positivity for Alcohol Use
NCT06030154
Gastrointestinal Interoception in Anorexia Nervosa
NCT05111977
Antiviral Treatment OF Cytomegalovirus IN Depression
NCT04724447
Neural Response to Inflammatory Challenge in Major Depressive Disorder
NCT04751331
Approach-Avoidance, Computational Framework for Predicting Behavioral Therapy Outcome (AAC-BeT)
NCT04426461
Modulating Repetitive Negative Thinking Related Brain Networks in Young Adults With Depression
NCT06219681
Neuroimaging Study for Decoding Emotional States and Identifying Neural Circuits to Disengage From Negative Thinking
NCT06254144
Contingency Management for Problematic Behavior Reduction in the Community
NCT06486584
Low Intensity Ultrasound Neuromodulation of Repetitive Negative Thinking In Depression
NCT05697172
Frontal Stimulation to Modulate Threat Sensitivity in Anxious Depression
NCT04948944
Cognitive Process-based Real-time fMRI Neurofeedback in MDD and Rumination
NCT04941066
Self-regulation of Prefrontal Cortex During Emotional Cognitive Control
NCT04543500
Affective Modulation of Positivity for Alcohol Use Disorder
NCT04278365
Augmented Mindfulness Training for Resilience in Early Life
NCT04053582
Frontoparietal Synchronization to Modulate Drug Craving in Opioid Use Disorder
NCT03907644
Neurocognitive Empowerment for Addiction Treatment (NEAT) in Opioid Use Disorder and Amphetamine Use Disorder
NCT03922646
Mindfulness for Resilience in Early Life
NCT03633903
Predicting Treatment Response to Exposure Therapy Using Carbon Dioxide
NCT03925987
Adherence to Antidepressant Treatment in Subjects With Depression
NCT03388164
Transcranial Direct Current Stimulation to Modulate Top-Down Regulation for Drug Craving in Methamphetamine Use Disorder
NCT03382379
Lipopolysaccharide (LPS) Challenge in Depression
NCT03142919
Cerebellar Neuromodulation to Enhance Fear Extinction and Predict Response to Exposure Therapy
NCT03275337
Examining the Effects of Reduced Environmental Stimulation on Anxiety
NCT03051074
TU Tough: Mental Toughness Training for College Success
NCT02982070
Breathing Intervention for Cardiac Anxiety
NCT02916550
Approach-Avoidance Conflict-a Multi-level Predictor for Therapy Response
NCT02807480
Effects of Reduced Environmental Stimulation on Eating Disorders
NCT02801084
Neurocognitive Predictors of Behavioral Therapy Response in Depression
NCT02602340
Neural Basis of Meal Related Interoceptive Dysfunction in Anorexia Nervosa
NCT02615119
Study of Ibuprofen Effects on Brain Function
NCT02507219
Influenza Challenge in Mood Disorders
NCT02415166
Examining the Effects of Reduced Environmental Stimulation on the Brain
NCT02452203
Latent Structure of Multi-level Assessments and Predictors of Outcomes in Psychiatric Disorders
NCT02450240
Neurophysiological and Immunological Effects of the Transition From Combustible to Electronic Cigarettes
NCT02433015
Effect of Amygdala Neurofeedback on Depressive Symptoms and Processing Biases
NCT02079610
Minocycline and Aspirin in the Treatment of Bipolar Depression
NCT01429272
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 5 |
| Phase 2 | 3 |
| Phase 3 | 1 |
| Phase 4 | 1 |
Therapeutic Areas
What is open in the Laureate Institute for Brain Research pipeline
14 recruiting of 45 indexed (31% open); 27 completed (60%).
Phase mix: 2 late (III/IV) vs 8 early (I/II) (early-phase heavy).
Top condition: Depression (5 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Laureate Institute for Brain Research: open-pipeline peers nationwide
Peers matched on 45 registered trials and 31% open enrollment, not the therapeutic-area sidebar.
Laureate Institute for Brain Research sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 45 trials (± recruiting share)
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections · 45 trials · 4% recruiting
- AIDS Malignancy Consortium · 45 trials · 11% recruiting
- Cambridge Health Alliance · 45 trials · 16% recruiting
- Carilion Clinic · 45 trials · 20% recruiting
Sponsors near 31% open enrollment (± trial volume)
- Philips Clinical & Medical Affairs Global · 31% recruiting · 45 trials
- Eko Devices · 31% recruiting · 16 trials
- Varian, a Siemens Healthineers Company · 31% recruiting · 16 trials
- Wright State University · 31% recruiting · 32 trials
Related
What to do with this Laureate Institute for Brain Research page
45 registered trials is a research-attention snapshot, not an endorsement of Laureate Institute for Brain Research or any single study.
- 14 of Laureate Institute for Brain Research's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Depression is the condition Laureate Institute for Brain Research studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Depression trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Laureate Institute for Brain Research pipeline card: 45 registered trials from official public datasets.Report a data error.